Description

This issue of Vital Signs, released on May 17, 2010, provides a strategic overview of key issues and trends relating to prefilled syringes in drug delviery. Additionally, a company spotlight is provided for Vanda Pharmaceuticals, a biopharmaceutical company utilizing novel technologies, including genetics and genomics, to discover, develop and commercialize drug candidates for central nervous system (CNS) disorders. Reimbursement and regulatory news from the FDA is also provided for the week of April 26, 2010.